Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Update

Dermata Therapeutics, Inc. (NASDAQ:DRMA) was the recipient of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 188,800 shares, a decline of 23.8% from the February 28th total of 247,700 shares. Currently, 4.7% of the company’s shares are sold short. Based on an average trading volume of 349,300 shares, the short-interest ratio is currently 0.5 days.

Dermata Therapeutics Price Performance

Shares of Dermata Therapeutics stock opened at $1.18 on Monday. The company has a market capitalization of $6.41 million, a P/E ratio of -0.07 and a beta of 0.65. The business has a 50-day moving average of $1.21 and a two-hundred day moving average of $1.31. Dermata Therapeutics has a 1 year low of $1.00 and a 1 year high of $6.67.

About Dermata Therapeutics

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.